Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy

scientific article published on 29 March 2017

Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/INFDIS/JIX013
P932PMC publication ID5426376
P698PubMed publication ID28368497

P50authorHenrik ZetterbergQ6252048
Dietmar FuchsQ38801487
Lars HagbergQ97650293
Serena SpudichQ114411897
Richard W PriceQ124366832
P2093author name stringDieter J Meyerhoff
Magnus Gisslén
Fang-Yong Li
Kevin Robertson
Elham Rahimy
P2860cites workThe effects of psychostimulant drugs on blood brain barrier function and neuroinflammationQ21129283
Acquired immunodeficiency syndrome and the blood-brain barrierQ24653985
Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infectionQ24810504
Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degenerationQ33610029
Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activationQ34099733
Lower brain glutamate is associated with cognitive deficits in HIV patients: A new mechanism for HIV‐associated neurocognitive disorderQ34257820
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER StudyQ34370880
Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infectionQ34466521
Change in brain magnetic resonance spectroscopy after treatment during acute HIV infectionQ34508049
Progressive increase in central nervous system immune activation in untreated primary HIV-1 infectionQ34678105
Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detectionQ34776835
The role of medical imaging in defining CNS abnormalities associated with HIV-infection and opportunistic infectionsQ34787585
Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patientsQ35093695
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burdenQ35164448
Primary HIV type 1 infectionQ35779940
Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid.Q36072424
Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV InfectionQ36250205
Central nervous system viral invasion and inflammation during acute HIV infectionQ36376213
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.Q36673315
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infectionQ36796560
Diagnosis and management of acute HIV infectionQ36821653
Cerebral white matter integrity during primary HIV infectionQ37028677
Matrix metalloproteinase levels in early HIV infection and relation to in vivo brain statusQ37283984
HIV and neurocognitive dysfunctionQ38122104
Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infectionQ38429930
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration.Q38433078
Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infectionQ38860933
Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference valuesQ40833195
Calculating correlation coefficients with repeated observations: Part 2--Correlation between subjectsQ41919008
Calculating correlation coefficients with repeated observations: Part 1--Correlation within subjectsQ41972849
Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals--correlation with cerebrospinal fluid HIV-1 RNA and neopterin levelsQ43796945
Human immunodeficiency virus infection of the brain. I. Virus isolation and detection of HIV specific antibodies in the cerebrospinal fluid of patients with varying clinical conditionsQ45833251
Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluidQ45843920
Early viral brain invasion in iatrogenic human immunodeficiency virus infectionQ45868985
Longitudinal characterization of depression and mood states beginning in primary HIV infectionQ46834428
Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replicationQ47672132
Early penetration of the blood-brain-barrier by HIV.Q48125248
Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrierQ48230350
Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratioQ48353899
Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysisQ48413062
Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patientsQ48899585
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.Q49015259
HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment.Q55135038
Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study GroupQ64130059
P433issue7
P407language of work or nameEnglishQ1860
P921main subjectblood–brain barrierQ221694
P304page(s)1132-1140
P577publication date2017-04-01
P1433published inJournal of Infectious DiseasesQ4051141
P1476titleBlood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy
P478volume215

Reverse relations

cites work (P2860)
Q52699607Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?
Q64974601Clinical characteristics and cerebro-spinal fluid cytokine changes in patients with acquired immunodeficiency syndrome and central nervous system infection.
Q54217355Distribution of HIV RNA in CSF and Blood is linked to CD4/CD8 Ratio During Acute HIV.
Q93383858Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals
Q66678727Gamma Interferon Alters Junctional Integrity via Rho Kinase, Resulting in Blood-Brain Barrier Leakage in Experimental Viral Encephalitis
Q51762497Global HIV neurology: a comprehensive review.
Q57807608HIV Cerebrospinal Fluid Escape and Neurocognitive Pathology in the Era of Combined Antiretroviral Therapy: What Lies Beneath the Tip of the Iceberg in Sub-Saharan Africa?
Q46617628HIV-1 counteracts an innate restriction by amyloid precursor protein resulting in neurodegeneration
Q52561597Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary HIV Infection.
Q92360041Markers of CNS Injury in Adults Living With HIV With CSF HIV Not Detected vs Detected <20 Copies/mL
Q99419745Methamphetamine and Cannabis: A Tale of Two Drugs and their Effects on HIV, Brain, and Behavior
Q89483369Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART)
Q64076275Targeting the HIV-infected brain to improve ischemic stroke outcome
Q53075373The Aging Brain With HIV Infection: Effects of Alcoholism or Hepatitis C Comorbidity.

Search more.